Floatz logo

Venetoclax

Acute Myeloid Leukemia With T(16;16)(P13;Q22)

The First Affiliated Hospital of Soochow UniversitySmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Acute Myeloid Leukemia With T(16;16)(P13;Q22) cohort.

Asset / SponsorPhaseRating
Avapritinib
The First Affiliated Hospital of Soochow University
Phase 1/2CCC

Same molecule, other indications

Venetoclax is also rated in:

Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveDormant
BBB
Indicative ·
72 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
BB
Indicative ·
70 / 100
View asset →
myeloid neoplasmDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →